Read our latest whitepaper for a comprehensive overview of AI-driven site selection and its potential to drive positive outcomes for patients.

Download your copy. ow.ly/heHU50R3UBP

#ClinicalTrials #AIInnovation #PatientOutcomes

Meet the ICON team at #BioKorea booth #Q15 and discuss the newest bio-health trends and technology.

Register at: ow.ly/qb7x50RnZ4O

Register today for insights from our #IRT expert, Mia Carter, who will be participating in a panel discussion on the future of IRT integration. ow.ly/5zI950RmROI

Meet ICON Biotech at Bio€quity Europe 2024, taking place in San Sebastián, Spain, May 12-14. Join our senior team who are attending to engage with biotech innovators, partners and investors at one of Europe’s largest biotech investor conferences.
ow.ly/BanN50RnXgl

We know what payers want - we've been offering expertise in managed markets and payer strategies for over 25 years. Stop by booth 2022 at AXS24 to talk with ICON’s experts from Market Access. ow.ly/EE2J50RcU44

#Asembia24

Learn practical advice for understanding and interpreting the dynamic regulatory landscape around data standardisation.

Our experts shared insights and guidance in our recent webinar. Watch it here: ow.ly/gWmX50R8oCY

Complex patient-centric clinical trials mean researchers manage greater volumes of data than ever. ICON’s Rose Kidd and The Scientist consider the implications. “Research results are only as reliable as the data on which they are based.” Read more: ow.ly/ZA4S50Rg8c1

ICON reports first quarter 2024 results. Quarter one revenue of $2,090.4 million representing an increase of 5.7% on prior year revenue and 5.4% on a constant currency basis. Read more ow.ly/yEUA50RnONy

Gain insight into the “how, when and where” patient advocacy can significantly impact the drug development process. Meet the ICON team at #WODCUS2024 to learn more. ow.ly/KI9V50ReXSF

Join ICON’s Thomas Liebers at #RAPS Euro Convergence from 6 – 8 May for insights on building global labeling processes to help drive efficient product development. ow.ly/Qy4250Rgfyf

Join the Jonathan Harris fireside chat on May 8 and gain insights on what fit-for-purpose sponsor oversight looks like in practice, during #OCTEurope2024 . ow.ly/OXam50Re0T4

Meet the ICON team at #DIA China, booth #CV16 and discuss the way of working on the lifecycle drug development in the Asia market. ow.ly/3NGE50RlWMo

Successful mRNA vaccines for COVID-19 have paved the way for personalised cancer therapy and have the potential to revolutionise cancer treatment with a highly tailored approach. Gain expert insight into the progress of mRNA vaccines for cancer here: ow.ly/3rTG50RlWeO

How important are specialty drugs in benefit decisions? We spoke with decision-makers from several different industries to find out and will present our insights during AXS24 in Las Vegas.
ow.ly/KHQa50RcTRq

#Asembia24

Human expertise meets AI innovation: Learn how our unique approach combines the strengths of both, to optimise site selection in clinical trials.

Read the whitepaper today. ow.ly/heHU50R3UBP

#HumanAI #ClinicalInnovation #ExpertInsights

Caroline Herdon, Principal Scientist at ICON will be sharing her expertise on considerations for the use of ProteinSimple’s automated immunoassay platform Simple Plex™ in regulated bioanalysis during her poster presentation at #WRIB .

Meet her: ow.ly/KrFl50R9hTA

On April 25, join ICON expert, Neena Nizar at 1:00 PM at #WorldOrphanUSA to hear about current best practices for diversity in clinical trials. Learn more. ow.ly/KI9V50ReXSF

Earlene Biggs, ICON Market Access, presented a Medicare Part D Price Negotiations poster at #AMCP2024 .

Connect with us to learn more. ow.ly/hZyy50RjAUR

Training is the best predictor of standardised COA data collection performance – even more than experience.
Explore the value of rater training for successful COAs: ow.ly/kAB550R9gir

Are you attending the CDISC+TMF Europe Interchange in Berlin?
Join us on April 25 for insights on the TMF Reference Model Exchange Mechanism. ICON’s Virendra Alate and a panel of experts will explore the benefits and barriers of this emerging standard. ow.ly/q68q50Rj3Oc